SEC Form 4 · accession 0001250853-18-000135
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ernest Mario
Director
Period of report
Oct 29, 2018
Accepted (ET)
Oct 31, 2018 · 6:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 29, 2018 | M | 833 | $1.37 | A | 125,000 | D | |
| Common Stock | Oct 29, 2018 | M | 44,000 | $3.45 | A | 169,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.37 | Oct 29, 2018 | M | 833 | D | — | Aug 28, 2023 | Common Stock | 833 | 0 | D |
| Stock Option (right to buy)F2 | $3.45 | Oct 29, 2018 | M | 44,000 | D | — | Jan 7, 2026 | Common Stock | 44,000 | 0 | D |
Explanation of responses
- F1The option, representing a right to purchase a total of 20,000 shares, became exercisable as to 5,000 shares beginning on August 29, 2014, which was the first anniversary of the date on which the option was granted, and the remaining shares vested in equal monthly installments over the following 36 months.
- F2The option, representing a right to purchase a total of 44,000 shares, became exercisable in four equal quarterly installments following the date of grant, which was January 8, 2016.